TP53 and non-small cell lung carcinoma: Collectively, this study provided a predictor, UBL biological process gene mutation status, that could be used to distinguish potential responders from non-responders to atezolizumab as second-line therapy among NSCLC patients, with a more promising predictive value in TP53 mutation-negative subgroups.